PMID- 28581269
OWN - NLM
STAT- MEDLINE
DCOM- 20180326
LR  - 20181113
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Print)
IS  - 1011-8934 (Linking)
VI  - 32
IP  - 7
DP  - 2017 Jul
TI  - Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: 
      Efficacy, Safety, and Clinical Response Predictors.
PG  - 1124-1130
LID - 10.3346/jkms.2017.32.7.1124 [doi]
AB  - Allergen-specific immunotherapy is the only causal treatment for allergic 
      diseases. However, the efficacy of immunotherapy may vary around the world due to 
      differences in climate, the nature of aero-allergens and their distribution. The 
      aim of this study was to describe the effects of subcutaneous immunotherapy 
      (SCIT) in Korean adults with allergic asthma (AA). As a retrospective cohort 
      study, we reviewed medical records for 627 patients with AA in Korea who were 
      sensitized to house dust mite (HDM) and/or pollens and who underwent SCIT with 
      aluminum hydroxide adsorbed allergen extract from 2000 to 2012. Rates of 
      remission, defined as no further requirement of maintenance medication, over time 
      were determined by means of life tables and extension of survival analysis. 
      Herein, 627 asthmatic patients achieved remission within a mean of 4.7 +/- 0.2 
      years. The cumulative incidence rates of remission from AA were 86.9% upon 
      treatment with SCIT. Baseline forced expiratory volume in the first second (FEV1) 
      >/= 80% (hazard ratio [HR], 3.10; 95% confidence interval [CI], 1.79-5.39; P < 
      0.001), and maintenance of immunotherapy for more than 3 years (HR, 1.82; 95% CI, 
      1.21-2.72; P = 0.004) were significant predictors of asthma remission during 
      SCIT. In 284 patients on SCIT with HDM alone, initial specific immunoglobulin E 
      (IgE) levels to Dermatophagoides pteronyssinus and Dermatophagoides farinae did 
      not show significant difference between remission and non-remission group after 
      adjusting demographic variables. In conclusion, SCIT was effective and safe 
      treatment modality for patients with AA. Initial FEV1 >/= 80% and immunotherapy 
      more than 3 years were found to be associated with favorable clinical responses 
      to SCIT.
CI  - (c) 2017 The Korean Academy of Medical Sciences.
FAU - Lee, Ji Ho
AU  - Lee JH
AUID- ORCID: 0000-0001-8744-156X
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Kim, Su Chin
AU  - Kim SC
AUID- ORCID: 0000-0002-8890-6143
AD  - Clinical Trial Center, Ajou University Medical Center, Suwon, Korea.
FAU - Choi, Hyunna
AU  - Choi H
AUID- ORCID: 0000-0002-4812-8797
AD  - Clinical Trial Center, Ajou University Medical Center, Suwon, Korea.
FAU - Jung, Chang Gyu
AU  - Jung CG
AUID- ORCID: 0000-0001-9163-9253
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Ban, Ga Young
AU  - Ban GY
AUID- ORCID: 0000-0002-7961-742X
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Shin, Yoo Seob
AU  - Shin YS
AUID- ORCID: 0000-0002-9855-3185
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Nahm, Dong Ho
AU  - Nahm DH
AUID- ORCID: 0000-0001-5253-6577
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Park, Hae Sim
AU  - Park HS
AUID- ORCID: 0000-0003-2614-0303
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Ye, Young Min
AU  - Ye YM
AUID- ORCID: 0000-0002-7517-1715
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea. ye9007@ajou.ac.kr.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - 0 (Allergens)
RN  - 0 (Antigens, Dermatophagoides)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
SB  - IM
MH  - Adult
MH  - Allergens/*administration & dosage/immunology
MH  - Aluminum Hydroxide/chemistry
MH  - Animals
MH  - Antigens, Dermatophagoides/*administration & dosage/immunology
MH  - Asthma/*therapy
MH  - Climate
MH  - Dermatophagoides farinae/*immunology
MH  - Dermatophagoides pteronyssinus/*immunology
MH  - Desensitization, Immunologic/adverse effects/*methods
MH  - Female
MH  - Forced Expiratory Volume/physiology
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Injections, Subcutaneous
MH  - Male
MH  - Pollen/*immunology
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - Rhinitis, Allergic, Seasonal/immunology/*therapy
PMC - PMC5461316
OTO - NOTNLM
OT  - Allergen-Specific Immunotherapy
OT  - Allergic Asthma
OT  - House Dust Mites
OT  - Remission
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2017/06/06 06:00
MHDA- 2018/03/27 06:00
PMCR- 2017/07/01
CRDT- 2017/06/06 06:00
PHST- 2017/01/10 00:00 [received]
PHST- 2017/04/10 00:00 [accepted]
PHST- 2017/07/01 00:00 [pmc-release]
PHST- 2017/06/06 06:00 [entrez]
PHST- 2017/06/06 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
AID - 32.1124 [pii]
AID - 10.3346/jkms.2017.32.7.1124 [doi]
PST - ppublish
SO  - J Korean Med Sci. 2017 Jul;32(7):1124-1130. doi: 10.3346/jkms.2017.32.7.1124.